Dynavax is giving up work on its combination vaccine for tetanus, diphtheria and acellular pertussis (Tdap) after mulling phase 1 data for the shot. | Dynavax is giving up on its combination vaccine ...

About Sanofi SA (ADR) and Novartis AG (ADR ... meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides ...

IGRA presents more significant advantages than tuberculin skin tests because these are more accurate and sensitive, ...

Diphtheria and tetanus toxoids and acellular pertussis adsorbed, hepatitis B (recombinant) and inactivated poliovirus vaccine combined ... Lantus vial or cartridge (Sanofi-Aventis) 28 days ...

French drugmaker Sanofi faced controversy in May with a (quickly back-pedalled) suggestion from its CEO that the US would be the first country to benefit from access to its vaccine, once available ...

Novavax has made a smaller splash in the U.S. Covid-19 vaccine market than it had hoped. But it's betting on licensing deals ...

From the company's own site, we can see this pharma brand has a diversified portfolio of therapies across multiple clinical ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Sanofi has added to its vaccine pipeline with an agreement to acquire Austria's Origimm Biotechnology and its vaccine-based immunotherapy for people with acne. The French group said that ORI-001 ...

A study in the Journal of the American Chemical Society reports steps toward making inhalable mRNA medicines a possibility.

The US Food and Drug Administration (FDA) has removed the clinical hold on the Investigational New Drug (IND) application for ...